Login to Your Account



Clinic Roundup


Monday, April 11, 2011
StemCells Inc., of Palo Alto, Calif., discontinued a Phase Ib trial of HuCNS-SCA human neuronal stem cells in neuronal ceroid lipofuscinosis (NCL) due to lack of patient accrual. Phase I safety studies were completed in 2009 in six patients with advanced NCL. The Phase Ib trial was to evaluate the therapy in six early stage patients. However, no eligible patients have been found after six months of searching.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription